Navigation Links
Lotrel, a Single-Pill Combination for Treating High Blood Pressure, Reduced Cardiovascular Events by 20% in High-Risk Patients
Date:3/31/2008

ponsored by the National Heart, Lung and Blood Institute recommend initial combination therapy of two medications that work differently for patients who have a systolic blood pressure of 20 mmHg and a diastolic blood pressure of 10 mmHg over target goal. Systolic blood pressure is the pressure of blood flow as the heart beats and pushes blood throughout the body. Diastolic blood pressure is between heart beats, as your heart rests and refills with blood.

Approximately 73 million adults (nearly one in three) in the US have high blood pressure. It has been estimated that most adults with high blood pressure also have additional health problems that increase their risk for cardiovascular events.

Novartis: strength in cardiovascular and metabolic diseases

Novartis is focused on improving the lives of the hundreds of millions of people with diseases of the cardiovascular and metabolic systems. As a global leader and innovator in cardiovascular and metabolic health, Novartis provides novel therapies and support programs to treat high blood pressure and major public health issues. The strength of Novartis lies in its broad range of renin-angiotensin system (RAS) based therapies for the treatment of high blood pressure, which include the most prescribed angiotensin-receptor-blocker, the first approved oral direct renin inhibitor and a single agent combining two of the most prescribed antihypertensive medicines. Novartis has an extensive clinical research program in hypertension involving more than 100,000 patients. Novartis is dedicated to helping physicians and patients address cardiovascular and metabolic health through effective medicines and an ongoing commitment to education, support and research.

Disclaimer

The foregoing release contains forward-looking statements that can be identified by terminology such as "will", "suggest", "committed", or similar expressions, or by express or implied discussions regarding potential new indicatio
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Abbotts Phase III Studies of Investigational TriLipix(TM) (ABT-335), in Combination With Statins, Meets Primary Endpoints on Improving LDL, Triglycerides and HDL
2. ISTA Pharmaceuticals Announces Physician-Sponsored Clinical Study of Xibrom(TM) Combination Therapy with Lucentis(R)
3. New 48-Week Efficacy and Safety Data Presented for INTELENCE(TM) (etravirine) as Part of HIV Combination Therapy
4. Cogentus Pharmaceuticals Begins Clinical Study to Confirm the Full Antiplatelet Benefit of New Combination Medicine CGT-2168
5. First Patient Enrolled in Cogentus Pharmaceuticals Pivotal Phase 3 Trial of Novel Combination Medicine
6. Pharmion and MethylGene Start Phase 2 Combination Clinical Trial With MGCD0103 and Vidaza(R) in Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
7. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
8. New Drug Combination is Able to Eradicate Breast Metastases in Mice
9. Data Presented at 2007 ASH Meeting Demonstrate Activity of Forodesine HCl as a Single Agent or in Combination With Bendamustine in Certain Types of Leukemia and Lymphoma
10. Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Stem Cell Transplantation
11. Avicena Announces Positive Phase II Data for a Combination Trial Involving AL-08 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... Research and Markets ( ... "North American Active Wound Care Market by ... & Ulcer), by End-User (In-Patient, & Out-Paient) - ... their offering. ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,The North ... grow at a CAGR of 3.1% from 2014 ...
(Date:5/21/2015)... REDWOOD CITY, Calif. , May 21, 2015  Cardica, ... 20, 2015, new employee Greg Watson , the company,s ... 400,000 shares of the company,s common stock, at a per ... May 20, 2015. The stock option was granted pursuant to ... board of directors in May 2015 under Rule 5653(c)(4) of ...
(Date:5/21/2015)... CAMBRIDGE, England , May 21, ... zur Bekämpfung von Arzneimittelfälschungen - Zwecks ... eines Arzneimittelprüfdienstes wird auf EG-Mitgliedstaaten verwiesen, ... Pilotsysteme betrieben werden.  Wählen Sie ein ... Bei der Richtlinie zur Bekämpfung von ...
Breaking Medicine Technology:North American Active Wound Care Market 2015-2019 with Smith and Nephew, Molyncke HealthCare & ConvaTec Dominating 2Cardica Announces New Employment Inducement Grant 2EU-Arzneimittel-Richtlinie für gefälschte Medikamente; Aegate-Zusammenfassung als reale Bewertung aus Belgien 2EU-Arzneimittel-Richtlinie für gefälschte Medikamente; Aegate-Zusammenfassung als reale Bewertung aus Belgien 3
... Technology advances have had a profound effect on ... a constantly evolving communication environment, companies need to continuously ... It is challenging, however, to gauge the effectiveness of ... of today,s internal and external communication options. ...
... Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today ... Biosciences, will be presenting at the 2011 Credit Suisse Annual ... live presentation takes place on Wednesday, November 9, 2011 at ... 1:00 p.m. Pacific Time.  The presentation will be webcast and ...
Cached Medicine Technology:Internal and External Communication Insights: Effective Approaches for Reaching Clients and Co-Workers 2
(Date:5/25/2015)... (PRWEB) May 25, 2015 A recent report ... states 1,000 persons have died as a direct result of ... This marks a 33% rise in overdose deaths attributed to ... Baker, “This issue doesn’t care about geography. This issue doesn’t ... issue doesn’t care about class.” As the state of Mass. ...
(Date:5/25/2015)... 2015 ProDrop Light Show allows users ... light backdrops with a click of a mouse. Users have full ... all within Final Cut Pro X. , ProDrop Light Show gives ... zones, kaleidoscope and much more leaving infinite possibilities all within Final ... zones and text presets, users can apply their very own media ...
(Date:5/25/2015)... Americas announces major investment in new technology and personnel ... Medical Answering Service customers. Through a combination of ... provides a seamless transition between a health care provider’s ... patient satisfaction. , Tunstall is pleased to ... expanded facilities and the latest telecommunication software and hardware ...
(Date:5/24/2015)... (PRWEB) May 25, 2015 Pacific Prime has announced ... part report looking at the cost of individual international health ... Article 2 looks at the cost of health insurance in six ... Focusing on, Hong Kong , ... the UAE , the UK , ...
(Date:5/24/2015)... (PRWEB) May 24, 2015 For people ... and Chinese Enterokinase Industry, 2009-2019 Market Research Report would ... is an exhaustive study on the present market scenario ... insight into the growing Chinese market of this industry. ... the overall status of the manufacturers in this industry. ...
Breaking Medicine News(10 mins):Health News:Opioid Deaths Increase by 33 Percent Since 2012 in Mass. 2Health News:Developers at Pixel Film Studios Release of ProDrop Light Show for Final Cut Pro X. 2Health News:Tunstall Introduces New Medical Answering Service for the 21st Century Practice 2Health News:Pacific Prime Releases 2nd Article of Cost of Health Insurance Report 2Health News:Global and Chinese Enterokinase Industry 2009-2019 Market Research Report Now Available at RnRMarketResearch.com 2Health News:Global and Chinese Enterokinase Industry 2009-2019 Market Research Report Now Available at RnRMarketResearch.com 3Health News:Global and Chinese Enterokinase Industry 2009-2019 Market Research Report Now Available at RnRMarketResearch.com 4
... Choices ( http://www.nhs.uk ), the,digital ,front door, to the ... to see both the physical and financial cost of ... information, the interactive calculator,( http://www.nhs.uk/Tools/Pages/Smoking.aspx ) enables users to ... up how much you could save over,one to ten ...
... 11 In this 90 minute episode, Dr. Drew,reunites several ... they left treatment. Drew reveals who has relapsed, who has ... is comprised of,recovering addicts and fans of the show, will ... happened over the season., (Photos: ...
... suggests eating foods such as whole grains cuts risk ... -- Increased consumption of magnesium-rich foods such as whole ... which occurs when blood flow to the brain is ... the Karolinska Institute in Stockholm analyzed the diets and ...
... ALLEGAN, Mich., March 11 Perrigo Company,(Nasdaq: ... final approval,from the U.S. Food and Drug Administration (FDA) ... Foam, 0.05%., The product is a topical corticosteroid ... the scalp. Sales for the brand, Olux(R),Foam, 0.05%, were ...
... Verathon(R) is pleased to,announce a new Small Child ... instrument with patent-pending NeuralHarmonics(TM),Technology. Small Child Mode enables ... children weighing less than 60 pounds and,standing less ... used for adult,patients. This enhanced BladderScan(R) BVI 9400 ...
... . , Malignant tumors have usually lost their ... apoptosis. Therefore, tumors are often resistant to chemotherapy or ... cells to commit suicide. , This resistance to ... numerous molecular switches regulating the self-destruction process. This is ...
Cached Medicine News:Health News:Magnesium May Lower Risk for Some Strokes in Male Smokers 2Health News:Perrigo Company Receives Final Approval on Clobetasol Propionate Foam 2Health News:Perrigo Company Receives Final Approval on Clobetasol Propionate Foam 3Health News:Verathon Inc. Launches Enhanced BladderScan(R) Bladder Volume Instrument With Small Child Mode 2Health News:Verathon Inc. Launches Enhanced BladderScan(R) Bladder Volume Instrument With Small Child Mode 3Health News:Paradigm shift: Switch for programmed cell death promotes spread of glioblastoma 2
Used to provide drainage of urine from the bladder. All-silicone construction provides maximum softness and biocompatibility for enhanced patient comfort. Supplied sterile in peel-open packages. Inte...
Used for stenting the urethra during hypospadias or epispadias repair and to promote postoperative drainage of the bladder. Supplied sterile in peel-open packages. Intended for one-time use....
... catheter or instrument introduction. The dual ... peeled away and removed. The maximum ... to be introduced should be measured ... sheath. Supplied sterile in peel-open packages. ...
... temporary internal drainage from ... the bladder. Supplied sterile ... for one-time use. CAUTION: ... C-Flex® and Sof-Flex® stents ...
Medicine Products: